Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression

Prostaglandins and Other Lipid Mediators

Volumn 93, Issue 3-4, 2010, Pages 113-119

  Li, Wei Zhong ^a   Huo, Qiu Ju ^a   Wang, Xiao Yan ^a   Xu, Fang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; Celecoxib; Cell adhesion; Cell movement; Matrix metalloproteinase 2; Squamous cell

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE A; MATRIGEL; PROSTAGLANDIN E2;

ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL COUNT; CELL INVASION; CELL MIGRATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; WESTERN BLOTTING;

CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOWN-REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; PYRAZOLES; SULFONAMIDES; TONGUE NEOPLASMS;

EID: 78149408889     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.08.001     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225.
2. Sano D., Myers J.N. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007, 26:645.
3. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993, 73:161.
4. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993, 9:541.
5. Yoon S.O., Park S.J., Yun C.H., Chung A.S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003, 36:128.
6. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays 1992, 14:455.
7. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9.
8. Kusukawa J., Sasaguri Y., Shima I., Kameyama T., Morimatsu M. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol 1993, 99:18.
9. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260.
10. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997, 378:151.
11. Sato H., Takino T., Okada Y., et al. matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61.
12. Katayama A., Bandoh N., Kishibe K., et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004, 10:634.
13. Schnaper H.W., Grant D.S., Stetler-Stevenson W.G., et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993, 156:235.
14. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 2:1063.
15. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306.
16. Uefuji K., Ichikura T., Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000, 6:135.
17. Chan A.T., Giovannucci E.L., Meyerhardt J.A., Schernhammer E.S., Wu K., Fuchs C.S. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008, 134:21.
18. Genkinger J.M., De Vivo I., Stampfer M.J., Giovannucci E., Michaud D.S. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer 2007, 120:2221.
19. Jacobs E.J., Rodriguez C., Mondul A.M., et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005, 97:975.
20. Fortuny J., Johnson C.C., Bohlke K., et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 2007, 5:1154.
21. Shiotani H., Denda A., Yamamoto K., et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001, 61:1451.
22. de Groot D.J., de Vries E.G., Groen H.J., de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007, 61:52.
23. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J Cancer Res Clin Oncol 2001, 127:411.
24. Méric J.B., Rottey S., Olaussen K., et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006, 59:51.
25. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946.
26. Grubbs C.J., Lubet R.A., Koki A.T., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000, 60:5599.
27. Li N., Sood S., Wang S., Fang M., Wang P., Sun Z. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005, 11:2089.
28. Nishimura N., Urade M., Hashitani S., et al. Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 2004, 33:614.
29. Terakado N., Shintani S., Yano J., et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 2004, 40:383.
30. Leung E., McArthur D., Morris A., Williams N. Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression. Dis Colon Rectum 2008, 51:342.
31. Larkins T.L., Nowell M., Singh S., Sanford G.L. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006, 6:181.
32. Kurihara Y., Hatori M., Ando Y., et al. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis 2009, 26:425.
33. Kwak Y.E., Jeon N.K., Kim J., Lee E.J. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann NY Acad Sci 2007, 1095:99.
34. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004, 67:1469.
35. Maier T.J., Janssen A., Schmidt R., Geisslinger G., Grösch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005, 19:1353.
36. Pang R.P., Zhou J.G., Zeng Z.R., et al. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Cancer Lett 2007, 251:268.
37. Sansone P., Piazzi G., Paterini P., et al. Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med 2009, 13:3876.
38. Kismet K., Akay M.T., Abbasoglu O., Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004, 28:127.
39. Reich R., Martin G.R. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996, 51:1.